Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. J.Molner AS's Net Income for the
six
months ended in Dec. 2025 was €1.54 Mil. J.Molner AS's Revenue for the
six
months ended in Dec. 2025 was €0.60 Mil. Therefore, J.Molner AS's net margin for the quarter that ended in Dec. 2025 was 258.82%.
The historical rank and industry rank for J.Molner AS's Net Margin % or its related term are showing as below:
OTSE:MOLNR'
s Net Margin % Range Over the Past 10 Years
Min: -322.92 Med: -106.27 Max: 11.51
Current: 11.17
OTSE:MOLNR's Net Margin % is ranked better than 68.09% of 959
companies
in the Drug Manufacturers industry
Industry Median: 5.46
vs OTSE:MOLNR: 11.17
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
J.Molner AS Net Margin % Related Terms
J.Molner AS Net Margin % Historical Data
* Premium members only.
The historical data trend for J.Molner AS's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTSE:MOLNR vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
J.Molner AS Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's Net Margin % distribution charts can be found below:
* The bar in red indicates where J.Molner AS's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
J.Molner AS (OTSE:MOLNR) has a Net Margin % of 258.82% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on J.Molner AS and its competitors. According to the industry distribution chart, J.Molner AS ranks #306 out of 959 companies in the Drug Manufacturers industry, placing it in the top 31.9%.
Is J.Molner AS's Net Margin % too high?
J.Molner AS's current Net Margin % is 258.82%. The Drug Manufacturers industry median Net Margin % is 5.46. J.Molner AS's value of 258.82% is 4640.3% above this industry median. Based on the distribution chart, J.Molner AS ranks #306 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, J.Molner AS ranks #306 out of 959 companies for Net Margin %. This puts J.Molner AS in the upper half of its industry. The industry median Net Margin % is 5.46. J.Molner AS's value of 258.82% is 4640.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.46, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. J.Molner AS's current Net Margin % of 258.82% is 4640.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on J.Molner AS and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J.Molner AS's current Net Margin % is 258.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.62, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current Net Margin % is 258.82% and 4640.3% above the Drug Manufacturers industry median of 5.46. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current Net Margin % is 258.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?
Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued.
The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62.
GuruFocus considers J.Molner AS to be Fairly Valued.
Key valuation signals for OTSE:MOLNR:
Net Margin %: 258.82%
GF Value™: €19.62 vs. price of €18.90 (3.7% below fair value)
Industry Position: 4640.3% above the Drug Manufacturers median (#306 of 959)
No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score
Get the complete analysis for OTSE:MOLNR
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTSE:MOLNR has been successfully added to your 
